Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Chatenoud

Showing results (211-220 of 259) with videos related to

Pageof 26
Sort By:
British Journal of Cancer|February 5, 2009
Dietary glycemic load and gastric cancer risk in ItalyP Bertuccio, D Praud, L Chatenoud, et al.
Transplantation|June 1, 1986
Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agentP Vigeral, N Chkoff, L Chatenoud, et al.
European Cytokine Network|July 1, 1995
Role of interleukin-2 receptors in the suppressive effect of spleen cells from anti-CD3-treated miceA Ben-Amor, Leite-De-Moraes MdC, F Lepault, et al.
The American Journal of Clinical Nutrition|December 3, 1999
Refined-cereal intake and risk of selected cancers in italyL Chatenoud, C La Vecchia, S Franceschi, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|January 23, 2014
Quantification of circulating house dust mite-specific IL-4- and IL-13-secreting T cells correlates with rhinitis severity in asthmatic children and varies with the seasonsB Michaud, R Gouvis-Echraghi, S Candon, et al.
Transplantation Proceedings|February 1, 1990
First and second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection followed by testing for anti-OKT3 IgM and/or IgG immunizationS A Birkeland, J F Bach, L Chatenoud, et al.
Transplantation Proceedings|February 1, 1989
A randomized trial comparing the efficacy of OKT3 used to prevent or to treat rejectionH Kreis, N Chkoff, L Chatenoud, et al.
Transplantation|February 1, 1984
Nonsteroid antiinflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipientsH Kreis, N Chkoff, D Droz, et al.
Nephrologie|January 1, 1987
[Preventive treatment of rejection by the prolonged administration of OKT3: decrease of the immune response of the host]A Debure, N Chkoff, L Chatenoud, et al.
Kidney International|October 1, 1989
In vivo T cell preactivation in chronic uremic hemodialyzed and non-hemodialyzed patientsG Beaurain, C Naret, L Marcon, et al.
Pageof 26

Showing results (211-220 of 259) with videos related to

Sort By:
Pageof 26
British Journal of Cancer|February 5, 2009
Dietary glycemic load and gastric cancer risk in ItalyP Bertuccio, D Praud, L Chatenoud, et al.
Transplantation|June 1, 1986
Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agentP Vigeral, N Chkoff, L Chatenoud, et al.
European Cytokine Network|July 1, 1995
Role of interleukin-2 receptors in the suppressive effect of spleen cells from anti-CD3-treated miceA Ben-Amor, Leite-De-Moraes MdC, F Lepault, et al.
The American Journal of Clinical Nutrition|December 3, 1999
Refined-cereal intake and risk of selected cancers in italyL Chatenoud, C La Vecchia, S Franceschi, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|January 23, 2014
Quantification of circulating house dust mite-specific IL-4- and IL-13-secreting T cells correlates with rhinitis severity in asthmatic children and varies with the seasonsB Michaud, R Gouvis-Echraghi, S Candon, et al.
Transplantation Proceedings|February 1, 1990
First and second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection followed by testing for anti-OKT3 IgM and/or IgG immunizationS A Birkeland, J F Bach, L Chatenoud, et al.
Transplantation Proceedings|February 1, 1989
A randomized trial comparing the efficacy of OKT3 used to prevent or to treat rejectionH Kreis, N Chkoff, L Chatenoud, et al.
Transplantation|February 1, 1984
Nonsteroid antiinflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipientsH Kreis, N Chkoff, D Droz, et al.
Nephrologie|January 1, 1987
[Preventive treatment of rejection by the prolonged administration of OKT3: decrease of the immune response of the host]A Debure, N Chkoff, L Chatenoud, et al.
Kidney International|October 1, 1989
In vivo T cell preactivation in chronic uremic hemodialyzed and non-hemodialyzed patientsG Beaurain, C Naret, L Marcon, et al.
Pageof 26